Norah J. Shire

Sahlgrenska University Hospital — Sweden

Medicine · Health Sciences

31h-index5.6kcitations109works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(35), Hepatitis B Virus Studies(29), Cancer Immunotherapy and Biomarkers(26), Liver Disease Diagnosis and Treatment(24), Lung Cancer Treatments and Mutations(21)

Publications109 total

Repeated intravenous infusions of esketamine in inpatients with bipolar depression: A retrospective real-world study
Journal of Affective Disorders Reports·2024Open Access
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology·2023· 771 citedOpen Access
Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark
PLoS ONE·2023· 2 citedOpen Access
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
Lung Cancer·2023· 7 citedOpen Access
The HORIZON III retrospective exploratory analysis: HER2 expression amplification in colorectal cancer.
Journal of Clinical Oncology·2023· 2 cited
Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab
Frontiers in Immunology·2022· 7 citedOpen Access
Interferon gamma expression and mortality in unselected cohorts of urothelial bladder cancer patients
PLoS ONE·2022· 6 citedOpen Access
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
ESMO Open·2022· 202 citedOpen Access
PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study
Scientific Reports·2021· 10 citedOpen Access
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark
Cancer Epidemiology·2021· 2 cited
Abstract 489: Association between immune-mediated adverse events and survival in patients with metastatic non-small cell lung cancer treated with durvalumab and tremelimumab
Cancer Research·2021
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
Lung Cancer·2020· 52 citedOpen Access
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
PLoS ONE·2020· 85 citedOpen Access
ADRIATIC: Eine Phase-III-Studie mit Durvalumab ± Tremelimumab nach gleichzeitiger Radiochemotherapie für Patienten mit SCLC im Stadium Limited Disease
Pneumologie·2020
CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)
Pneumologie·2020
Adriatic: a Phase III Trial of Durvalumab plus /- Tremelimumab After Concurrent Chemoradiation for Patients with Limited Stage Small Cell Lung Cancer
Pure Amsterdam UMC·2020
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
Clinical Lung Cancer·2019· 64 citedOpen Access
Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection
Clinical Pharmacology & Therapeutics·2019Open Access
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Journal of Translational Medicine·2019· 10 citedOpen Access
<p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>
Cancer Management and Research·2019· 2 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Kenneth E. Sherman(17), Susan D. Rouster(10), Mohamed Tarek M. Shata(6), Guy Neff(6), Haiyi Jiang(5), Jason T. Blackard(5), Niels Reinmuth(4), Maximilian J. Hochmair(4), Libor Havel(4), Radha Railkar(4), Bernard J. Dardzinski(4), Christopher O’Brien(4), Jeffrey A. Welge(4), Luis Paz‐Ares(3), Yuanbin Chen(3), Katsuyuki Hotta(3), Dmytro Trukhin(3), Galina Statsenko(3), Mustafa Özgüroğlu(3), Jun Ho Ji(3)